

Genitourinary Steering Committee (GUSC) Update

**Clinical Trials and Translational Research
Advisory Committee Meeting
July 15, 2009**

George Wilding, M.D.

GUSC Co-Chairs

Eric Klein, M.D.

Cleveland Clinic

Urology

George Wilding, M.D.

Univ. of Wisconsin Carbone Cancer Center

Medical Oncology

Anthony Zietman, M.D.

Massachusetts General Hospital

Radiation Oncology

GUSC Members

Michael Atkins, M.D.

Donna Berry, Ph.D., R.N.

Bobbi Brady

William Dahut, M.D.

Colin Dinney, M.D.

Robert DiPaola, M.D.

Jan Dutcher, M.D.

Boris Freidlin, Ph.D.

Susan Halabi, Ph.D.

Philip Kantoff, M.D.

Adam Kibel, M.D.

Bhupinder Mann, M.D.

Margaret Mooney, M.D.

Ken Pienta, M.D.

Hank Porterfield

Seth Rosenthal, M.D.

Howard Sandler, M.D.

Paul Schultz, M.D.

Neal Shore, M.D.

Eric Small, M.D.

Cathy Tangen, Ph.D.

Ian Thompson, Jr., M.D.

Fred Waldman, M.D., Ph.D.

Benjamin Yeh, M.D.

SC Representatives

Bladder SPORE - 1

Community Medical Oncologists - 2

Community Radiation Oncologist - 1

Community Urologist - 1

Cooperative Group Disease Chairs - 6

Extramural Statisticians - 2

NCI Extramural Staff - 3

NCI Intramural staff - 1

Patient Advocates - 2

Prostate SPORES - 2

Renal SPORE - 1

Translational P01/R01 Scientists - 2

Institutional Affiliations

Alliance for Prostate Cancer Prevention

Beth Israel Deaconess Medical Center

Brigham and Women's Hospital

Carolina Urologic Research Center

Cedars-Sinai Medical Center

Cleveland Clinic

Dana Farber Cancer Institute

Duke University Medical Center

Fred Hutchinson Cancer Research Center

Life with Cancer Advisory Council

Massachusetts General Hospital

MD Anderson Cancer Center

Missouri Baptist Cancer Center

Montefiore Medical Center, Bronx, NY

National Cancer Institute

Radiation Oncology Center, Roseville, CA

Univ. of Medicine & Dentistry of New Jersey

University of California, San Francisco

University of Michigan

Univ. of Wisconsin Carbone Cancer Center

University of Montreal

UTHSC-San Antonio

Washington University

Cooperative Group Affiliations

Twenty four members list memberships in one or more Cooperative Groups:

ACRIN

CALGB

ECOG

NSABP (community oncology member)

NCIC

RTOG

SWOG

Timeline

February 2008 - Intergroup Transition Meeting

August 2008 - First Concept Reviewed

February 2009 - Prostate TF Formed

February 2009 - Face to Face at GU ASCO

Summer 2009 - Renal and Bladder TFs Forming

Concepts

Evaluated - 6

- **Approved - 2**
- **Revise and Resubmit - 1**
- **Disapprove - 1**
- **In progress - 2**

Approved Concepts

RTOG 0815-A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

Localized prostatic adenocarcinoma at intermediate risk for recurrence as determined by harboring one or more of the following intermediate-risk features: Gleason Score 7; PSA >10, ≤20; T-Stage T2b-T2c. Patients harboring all three of these risk factors who also have ≥ 50% of their biopsy cores positive will be ineligible for this trial.

RTOG 0815-A


S T R A T I F I C A T I O N S	<u>Number of Risk Factors</u>	R A N D O M I Z E D	<u>Arm 1</u>
	1. One risk factor		Dose-escalated RT alone
	2. Two or 3 risk factors*		
	<u>Comorbidity Status</u>		<u>Arm 2</u>
	1. ACE-27 score ≥ 2		Dose-escalated RT combined with
	2. ACE-27 score < 2		short-term (6 months) androgen
	<u>RT Modality</u>		blockade (LHRH agonist +
	1. Dose-escalated EBRT		antiandrogen)
	2. EBRT + LDR brachytherapy boost		
	3. EBRT + HDR brachytherapy boost		
<i>Intermediate risk factors: Gleason Score 7; PSA >10, ≤ 20; TStage T2b-T2c. *Patients with all three intermediate risk factors and $\geq 50\%$ of their sampled biopsy cores involved will <u>not</u> be eligible for this study.</i>			

Approved Concepts

CALGB-90802 Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors

Metastatic clear cell renal carcinoma who have had progressed on at least 1 prior VEGFR TKI therapies (no prior VEGFR binding agents or mTOR inhibitors allowed). Adequate organ function and ECOG PS 0-2 required.

CALGB-90802



5.2 Arms/Regimens

Each cycle is 28 days (4 weeks)

	AGENT	DOSE	ROUTE	SCHEDULE
ARM A	Everolimus	10 mg	PO	Daily
	Placebo		IV	D1 and D15
ARM B	Everolimus	10 mg	PO	Daily
	Bevacizumab	10 mg/kg	IV	D1 and D15

Prostate Task Force Co-Chairs

Michael Carducci, M.D.

Johns Hopkins
Medical Oncology

Deborah A. Kuban, M.D.

MD Anderson Cancer Center
Radiation Oncology

Andrew Stephenson, M.D.

Cleveland Clinic
Urology

Prostate Task Force Members

Sam Chang, Vanderbilt

Kim Chi, U. of British Columbia

Neil Fleshner, Princess Margaret

James Gulley, NCI

Maha Hussain, Univ. of Michigan

Kevin Kelly, Yale

W. Robert Lee, Duke

Glenn Liu, Univ. of Wisconsin

Jeff Michalski, Washington Univ.

Jim Mohler, Roswell Park

Charles Ryan, UCSF

Howard Scher, MSKCC/ PCCTC

Robert Uzzo, Fox Chase

Prostate Task Force

- **Formed January 2008**
- **Interacts with the IDSC and Investigational Drug Branch; Providing advice on several prostate specific agents**
- **Establishing a working group to develop a Clinical Trials Planning Meeting submission**
- **CRF Harmonization Working Group**
 - **Has met twice**
 - **Inventorying group's CRF**
 - **Working with CaBIG**

Successes

- **Established Steering Committee and Operating Procedures**
- **Initiated Concept Reviews**
- **Created Prostate Cancer Task Force**
- **Developed Reconciliation Procedure**
- **Started New Drug CTEP/Industry Advisory Process**
- **Arrived at Consensus Expectations**
- **Androgen Receptor Targeting**
- **Multiple new therapies in prostate and renal cancers**

Challenges

- **Intergroup cooperativeness**
- **Cooperative Group confidence in grant review expectations**

New Clinical Research Opportunities in GU Oncology

- **Androgen Receptor Targeting**
- **Multiple new therapies in
prostate and renal cancers**

Goals for Upcoming Year

- **Organize clinical trial planning meeting targeting the androgen receptor**
- **Create renal and bladder task forces**